PCI Biotech Holding ASA (PCIB) - Net Assets
Based on the latest financial reports, PCI Biotech Holding ASA (PCIB) has net assets worth Nkr12.52 Million NOK (≈ $1.32 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Nkr18.52 Million ≈ $1.95 Million USD) and total liabilities (Nkr6.01 Million ≈ $632.21K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PCI Biotech Holding ASA asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Nkr12.52 Million |
| % of Total Assets | 67.56% |
| Annual Growth Rate | -4.54% |
| 5-Year Change | -87.61% |
| 10-Year Change | -47.04% |
| Growth Volatility | 208.84 |
PCI Biotech Holding ASA - Net Assets Trend (2008–2024)
This chart illustrates how PCI Biotech Holding ASA's net assets have evolved over time, based on quarterly financial data. Also explore total assets of PCI Biotech Holding ASA for the complete picture of this company's asset base.
Annual Net Assets for PCI Biotech Holding ASA (2008–2024)
The table below shows the annual net assets of PCI Biotech Holding ASA from 2008 to 2024. For live valuation and market cap data, see market cap of PCI Biotech Holding ASA.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Nkr23.45 Million ≈ $2.47 Million |
-39.93% |
| 2023-12-31 | Nkr39.04 Million ≈ $4.11 Million |
-31.98% |
| 2022-12-31 | Nkr57.40 Million ≈ $6.04 Million |
-49.55% |
| 2021-12-31 | Nkr113.79 Million ≈ $11.97 Million |
-39.87% |
| 2020-12-31 | Nkr189.24 Million ≈ $19.91 Million |
-25.74% |
| 2019-12-31 | Nkr254.83 Million ≈ $26.82 Million |
-25.04% |
| 2018-12-31 | Nkr339.95 Million ≈ $35.77 Million |
+712.47% |
| 2017-12-31 | Nkr41.84 Million ≈ $4.40 Million |
+219.75% |
| 2016-12-31 | Nkr13.09 Million ≈ $1.38 Million |
-70.45% |
| 2015-12-31 | Nkr44.28 Million ≈ $4.66 Million |
+385.89% |
| 2014-12-31 | Nkr9.11 Million ≈ $959.06K |
-79.00% |
| 2013-12-31 | Nkr43.40 Million ≈ $4.57 Million |
-37.74% |
| 2012-12-31 | Nkr69.71 Million ≈ $7.34 Million |
-24.67% |
| 2011-12-31 | Nkr92.53 Million ≈ $9.74 Million |
-12.23% |
| 2010-12-31 | Nkr105.42 Million ≈ $11.09 Million |
+200.56% |
| 2009-12-31 | Nkr35.08 Million ≈ $3.69 Million |
-28.85% |
| 2008-12-31 | Nkr49.30 Million ≈ $5.19 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to PCI Biotech Holding ASA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2233300000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Nkr22.33 Million | 95.22% |
| Common Stock | Nkr1.12 Million | 4.77% |
| Other Comprehensive Income | Nkr1.00K | 0.00% |
| Total Equity | Nkr23.45 Million | 100.00% |
PCI Biotech Holding ASA Competitors by Market Cap
The table below lists competitors of PCI Biotech Holding ASA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Groupimo SA
PA:ALIMO
|
$278.43K |
|
Sejahtera Bintang Abadi Textile Tbk
JK:SBAT
|
$278.51K |
|
Tan Delta Systems PLC
LSE:TAND
|
$280.64K |
|
Lytus Technologies Holdings PTV. Ltd. Common Shares
NASDAQ:LYT
|
$283.11K |
|
Virpax Pharmaceuticals Inc
NASDAQ:VRPX
|
$273.35K |
|
Stayble Therapeutics AB
ST:STABL
|
$271.50K |
|
Baltic Bridge S.A.
WAR:WIS
|
$271.38K |
|
M Winkworth PLC
LSE:WINK
|
$270.93K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PCI Biotech Holding ASA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 39,043,000 to 23,453,000, a change of -15,590,000 (-39.9%).
- Net loss of 16,417,000 reduced equity.
- Other factors increased equity by 827,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Nkr-16.42 Million | -70.0% |
| Other Changes | Nkr827.00K | +3.53% |
| Total Change | Nkr- | -39.93% |
Book Value vs Market Value Analysis
This analysis compares PCI Biotech Holding ASA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.11x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.01x to 0.11x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | Nkr6.52 | Nkr0.07 | x |
| 2009-12-31 | Nkr3.86 | Nkr0.07 | x |
| 2010-12-31 | Nkr8.82 | Nkr0.07 | x |
| 2011-12-31 | Nkr6.58 | Nkr0.07 | x |
| 2012-12-31 | Nkr5.10 | Nkr0.07 | x |
| 2013-12-31 | Nkr3.17 | Nkr0.07 | x |
| 2014-12-31 | Nkr0.77 | Nkr0.07 | x |
| 2015-12-31 | Nkr2.93 | Nkr0.07 | x |
| 2016-12-31 | Nkr0.81 | Nkr0.07 | x |
| 2017-12-31 | Nkr1.69 | Nkr0.07 | x |
| 2018-12-31 | Nkr11.99 | Nkr0.07 | x |
| 2019-12-31 | Nkr6.84 | Nkr0.07 | x |
| 2020-12-31 | Nkr5.08 | Nkr0.07 | x |
| 2021-12-31 | Nkr3.05 | Nkr0.07 | x |
| 2022-12-31 | Nkr1.54 | Nkr0.07 | x |
| 2023-12-31 | Nkr1.05 | Nkr0.07 | x |
| 2024-12-31 | Nkr0.63 | Nkr0.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PCI Biotech Holding ASA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -70.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -243.76%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 1.33x
- Recent ROE (-70.00%) is above the historical average (-81.56%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -23.07% | -154.40% | 0.13x | 1.11x | Nkr-16.31 Million |
| 2009 | -42.81% | -174.35% | 0.21x | 1.18x | Nkr-18.52 Million |
| 2010 | -13.22% | -133.47% | 0.09x | 1.09x | Nkr-24.48 Million |
| 2011 | -14.86% | -185.22% | 0.07x | 1.08x | Nkr-23.00 Million |
| 2012 | -36.24% | 0.00% | 0.00x | 1.12x | Nkr-32.23 Million |
| 2013 | -63.62% | -413.23% | 0.13x | 1.22x | Nkr-31.95 Million |
| 2014 | -393.24% | -491.16% | 0.36x | 2.24x | Nkr-36.75 Million |
| 2015 | -72.08% | -304.98% | 0.19x | 1.27x | Nkr-36.35 Million |
| 2016 | -245.94% | -307.25% | 0.47x | 1.71x | Nkr-33.49 Million |
| 2017 | -102.39% | -417.96% | 0.18x | 1.40x | Nkr-47.03 Million |
| 2018 | -10.23% | -362.86% | 0.03x | 1.05x | Nkr-68.78 Million |
| 2019 | -34.83% | -946.93% | 0.03x | 1.11x | Nkr-114.23 Million |
| 2020 | -38.17% | -980.44% | 0.04x | 1.11x | Nkr-91.16 Million |
| 2021 | -77.76% | -1410.49% | 0.05x | 1.19x | Nkr-99.86 Million |
| 2022 | -95.98% | -1159.89% | 0.07x | 1.11x | Nkr-60.84 Million |
| 2023 | -52.03% | -679.43% | 0.07x | 1.13x | Nkr-24.22 Million |
| 2024 | -70.00% | -243.76% | 0.22x | 1.33x | Nkr-18.76 Million |
Industry Comparison
This section compares PCI Biotech Holding ASA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $72,637,594
- Average return on equity (ROE) among peers: -108.57%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PCI Biotech Holding ASA (PCIB) | Nkr12.52 Million | -23.07% | 0.48x | $274.95K |
| Arcticzymes Technologies ASA (AZT) | $61.15 Million | -162.49% | 0.51x | $117.69 Million |
| Bergenbio ASA (BGBIO) | $12.05 Million | 0.00% | 0.48x | $7.75 Million |
| Circio Holding ASA (CRNA) | $-98.54 Million | 0.00% | 0.00x | $146.68 Million |
| Exact Therapeutics AS (EXTX) | $42.24 Million | -35.10% | 0.23x | $9.59 Million |
| Lytix Biopharma AS (LYTIX) | $107.89 Million | -87.37% | 0.36x | $80.92 Million |
| Nykode Therapeutics ASA (NYKD) | $242.56 Million | -49.57% | 0.21x | $110.82 Million |
| Oncoinvent ASA (ONCIN) | $146.33 Million | -105.98% | 0.40x | $23.00 Million |
| SoftOx Solutions AS (SOFTX) | $76.22 Million | -49.08% | 0.15x | $28.83 Million |
| Thor Medical ASA (TRMED) | $63.84 Million | -487.52% | 0.72x | $164.94 Million |
About PCI Biotech Holding ASA
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development of technologies and novel therapies through its photochemical technology platform. The company's technology platform consists of a proprietary small molecule photosensitiser and a light source; and develops photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vecto… Read more